Lv4
518 积分 2023-09-15 加入
Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
5天前
已完结
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
13天前
已完结
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
19天前
已完结
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
20天前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
20天前
已完结
Lisaftoclax: First Approval
21天前
已完结
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial
1个月前
已关闭
Daratumumab and venetoclax combined with CAGE for late R/R T-ALL/LBL patients: Single-arm, open-label, phase I study
1个月前
已完结
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
